Table 2.
Country | Region⁎ | Area⁎ | Seropositivity (%) | Overall number samples tested | Year Published | Author |
---|---|---|---|---|---|---|
Egypt | Africa | Northern Africa | 8.6% | 360 | 2022 | Fereig et al. [106] |
Libya | Africa | Northern Africa | 31% | 340 | 2010 | Ahmed et al. [79] |
Namibia | Africa | Sub-Saharan Africa | 23.0% | 52 | 2022 | Samkange et al. [46] |
Nigeria | Africa | Sub-Saharan Africa | 2.8% | 2827 | 2014 | Ogugua et al. [76] |
Uganda | Africa | Sub-Saharan Africa | 10.0% | 1446 | 2001 | Kabagambe et al. [73] |
Mexico | Americas | Latin America and the Caribbean | 9.3% | 12,127 | 2016 | Marin et al. [75] |
Tajikistan | Asia | Central Asia | 5.0% | 407 | 2016 | Rajala et al. [78] |
Cambodia | Asia | South-eastern Asia | 0.4% | 540 | 2022 | Siengsanan-Lamont et al. [50] |
Laos | Asia | South-eastern Asia | 1.4% | 1458 | 2018 | Burns et al. [19] |
Malaysia | Asia | South-eastern Asia | 0.9% | 119,799 | 2015 | Bamaiyi et al. [77] |
Thailand | Asia | South-eastern Asia | 1.4% | 94,722 | 2016 | Sagarasaeranee et al. [74] |
Thailand | Asia | South-eastern Asia | 46.6%⁎⁎ | 118 | 2022 | Rerkyusuke et al. [51] |
India | Asia | Southern Asia | 9.9–22.0% | 411 | 2020 | Leahy et al. [47] |
Iran | Asia | Southern Asia | 13.9% | 360 | 2014 | Ebrahimi et al. [107] |
Türkiye | Asia | Western Asia | 26.9% | 104 | 2016 | Bora et al. [108] |
Portugal | Europe | Southern Europe | 0.4% | 51,298 | 2013 | Coelho et al. [72] |
Spain | Europe | Southern Europe | 0.1% | 21 herds | 2000 | Reviriego et al. [71] |
Based on United Nations designations (https://unstats.un.org/unsd/methodology/m49/).
Symptomatic cases, not cross-sectional serology.